Andrew Cook, MD, on On-Going Clinical Research Efforts in the Head and Neck Cancer Space

Video

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss ongoing trials on treatment de-escalation and mitigating mucositis-related pain in head and neck cancer.

At the 2021 American Society for Radiation Oncology, CancerNetwork® spoke with Andrew Cook, MD, from Henry Ford Health System, about current ongoing trials in the head and neck cancer space, including efforts to better mitigate mucositis-related pain and treatment de-escalation.

Transcript:

At our specific institution, not myself, but some of my other colleagues are looking at an interesting question of what happens when you place an apparatus in a patient’s mouth to cool the oral mucosa while they’re undergoing radiation. [The intention is to] see if that may help to mitigate mucositis-related pain and improve quality of life going [for those] through treatments. That will be an exciting thing to see patients accrued on that and see what it may ultimately show. It’s an interesting idea. There are these other national trials looking at treatment deintensification of human papillomavirus positive oropharynx cancer, and those are going to be interesting. That's going to be a big direction of where the field is going.

Recent Videos
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Related Content